Metabolic associated fatty liver disease in patients with type 2 diabetes mellitus

Introduction. In patients with type 2 diabetes mellitus (T2DM) and obesity, the incidence of metabolically associated fatty liver disease (MAFLD) varies from 70 to 100%, and cardiovascular diseases are five times more common. Metabolic risk factors (RF) for fatty liver disease associated with T2DM are a dangerous combination, mutually aggravate each other’s course and escalate the number of adverse outcomes.

Aim. To investigate the frequency of metabolic risk factors in fatty liver disease in patients with type 2 diabetes.

Materials and methods. An observational cross-sectional (one-time) study was conducted with a retrospective analysis of inpatient observation cards of patients with type 2 diabetes (n = 179). MAFLD was established in the presence of hepatic steatosis, proven by ultrasound, in a patient with type 2 diabetes in combination with two or more metabolic disorders.

Results. The MAFLD phenotype in T2DM includes a high frequency of risk predictors: abdominal obesity and hypertension (100%), obesity (59.2%) and overweight (31.3%); meeting the criteria for MAFLD levels of HDL (94.4%), triglycerides (53.6%) and CRP (68.7%) in the blood plasma. Signs of sexual dimorphism were noted: in men: average age – 51.7%, more often normal (18.9%) and overweight (36.3%); most often AH in stage III (27.6%), complications include diabetic foot syndrome (3.9 times) and significant stenosis of the BCA (3 times). Elderly women (63.7%), were 1.5 times more likely to have obesity and stage III hypertension (13.2%), and suffered strokes more often than men (2.5 times).

Conclusions. The impact of genetic factors and various pathogenetic processes leads to the formation of a pathological pattern with a systemic disturbance of energy balance. To reduce the individual and population risk of vascular complications, it is necessary to control each of the components of MAFLD and achieve their target values.

1. Maev IV, Andreev DN, Kucheryavyy YuA. Metabolically associated fatty liver disease – a disease of the 21st century: A review. Consilium Medicum. 2022;24(5):325–332. (In Russ.) https://doi.org/10.26442/20751753.2022.5.201532.

2. Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–514. https://doi.org/10.1016/j.tem.2021.04.008.

3. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039.

4. Aznabakiyeva M, Avdeyeva E, Bashatova F, Guseinov K, Karimov T, Mayukova Zh, Imamatdinova A Clinically significant risk factors for nafld (literature review). Medicine, Science and Education. 2023;(1):23–30. (In Russ.) https://doi.org/10.24412/1609-8692-2023-1-23-30.

5. Ivashkin VT, Maevskaya MV, Zharkova MS, Kotovskaya YuV, Tkacheva ON, Troshina EA et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–140. (In Russ.) https://doi.org/10.22416/1382-4376-2022-32-4-104-140.

6. Stryuk RI, Sviridova MI, Mkrtumyan AM, Golikova AA. C-reactive protein as an indicator of risk of cardiovascular complications in patients with type 2 diabetes mellitus and its correction. Clinical Medicine (Russian Journal). 2016;94(9):683–687. (In Russ.) https://doi.org/10.18821/0023-2149-2016094-9-683-687.

7. Demidova TYu, Skuridina DV, Pervushina ES. Type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs. FOCUS. Endocrinology. 2023;4(1):6–15. (In Russ.) https://doi.org/10.15829/2713-0177-2023-17.

8. Garganeeva AA, Kuzheleva EA, Borel KN, Kondratyeva DS, Afanasiev SA. Diabetes mellitus type 2 and acute myocardial infarction: prognostic options for interaction in patients of different age groups. Diabetes Mellitus. 2018;21(2):105–112. (In Russ.) https://doi.org/10.14341/DM8828.

9. Dedov II, Mokrysheva NG, Mel’nichenko GA, Troshina EA, Mazurina NV, Ershova EV et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311–325. (In Russ.) https://doi.org/10.26442/20751753.2021.4.200832.

10. Ma RCW, Tong PCY. Epidemiology of Type 2 Diabetes. In: Holt RIG, BChir MB, Flyvbjerg A (eds.). Textbook of Diabetes. 6th ed. Wiley: Hoboken, NJ, USA; 2024, pp. 55–74. https://doi.org/10.1002/9781119697473.ch5.

11. Ha J, Hong OK, Han K, Kwon HS. Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults. Diabetes Res Clin Pract. 2024;212:111584. https://doi.org/10.1016/j.diabres.2024.111584.

12. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik JM. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999–2010. https://doi.org/10.1016/j.cgh.2024.03.006.

13. Caputo T, Gilardi F, Desvergne B. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. FEBS Lett. 2017;591(19):3061–3088. https://doi.org/10.1002/1873-3468.12742.

14. Barrera F, Uribe J, Olvares N, Huerta P, Cabrera D, Romero-Gómez M. The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease. Ann Hepatol. 2024;29(4):101501. https://doi.org/10.1016/j.aohep.2024.101501.

15. Ferdous SE, Ferrell JM. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Int J Mol Sci. 2024;25(16):8731. https://doi.org/10.3390/ijms25168731.

16. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. https://doi.org/10.1016/j.diabres.2018.02.023.

17. Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, Gourdy P. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63(3):453–461. https://doi.org/10.1007/s00125-019-05040-3.

18. Campesi I, Franconi F, Seghieri G, Meloni M. Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. Pharmacol Res. 2017;119:195–207. https://doi.org/10.1016/j.phrs.2017.01.023.

19. Ciarambino T, Crispino P, Leto G, Mastrolorenzo E, Para O, Giordano M. Influence of Gender in Diabetes Mellitus and Its Complication. Int J Mol Sci. 2022;23(16):8850. https://doi.org/10.3390/ijms23168850.

20. Beaudry KM, Devries MC. Sex-based differences in hepatic and skeletal muscle triglyceride storage and metabolism 1. Appl Physiol Nutr Metab. 2019;44(8):805–813. https://doi.org/10.1139/apnm-2018-0635.

21. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: Evidence, mechanisms and clinical implications. Endocr Rev. 2017;38(3):173–188. https://doi.org/10.1210/er.2016-1146.

22. Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021;74(3):1220–1233. https://doi.org/10.1002/hep.31806.

23. Huang DQ, Noureddin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(9):829–836. https://doi.org/10.1016/S2468-1253(23)00157-7.

24. En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–2148. https://doi.org/10.1136/gutjnl-2023-330110.

25. Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471–478. https://doi.org/10.1016/j.jhep.2022.11.010.

26. Stanimirovic J, Radovanovic J, Banjac K, Obradovic M, Essack M, Zafirovic S et al. Role of C-Reactive Protein in Diabetic Inflammation. Mediators Inflamm. 2022;2022:3706508. https://doi.org/10.1155/2022/3706508.

27. Kanmani S, Kwon M, Shin MK, Kim MK. Association of C-reactive protein with risk of developing type 2 Diabetes mellitus, and role of obesity and hypertension: a large population-based Korean cohort study. Sci Rep. 2019;9(1):4573. https://doi.org/10.1038/s41598-019-40987-8.

28. Yang M, Qiu S, He Y, Li L, Wu T, Ding N et al. Genetic ablation of C-reactive protein gene confers resistance to obesity and insulin resistance in rats. Diabetologia. 2021;64(5):1169–1183. https://doi.org/10.1007/s00125-02105384-9.

29. Kurauti MA, Costa-Júnior JM, Ferreira SM, Santos GJ, Sponton CHG, Carneiro EM et al. Interleukin-6 increases the expression and activity of insulin-degrading enzyme. Sci Rep. 2017;7(1):46750. https://doi.org/10.1038/srep46750.

30. Nisar M, Iqbal MU. Influence of hs-CRP, IL-6 and TNF-α and it’s role in dyslipidemia and type 2 diabetes in population of Karachi, Pakistan. Pak J Pharm Sci. 2021;34(3(Special)):1217–1225. Available at: https://www.pjps.pk/uploads/pdfs/34/3/Special/6-9286-SP.pdf